Cambridge-based biotechnology firm Tolemy Bio has successfully secured €1.4 million in a pre-seed funding round to advance its innovative platform. The investment, led by Norrsken Evolve, will accelerate the development of the company's AI-enabled technology for cell biology research. This new capital injection marks a significant step for the startup in its mission to revolutionize biopharma development.
Addressing a Core Challenge in Biopharma
Tolemy Bio addresses a persistent challenge within the biopharmaceutical and cell biology sectors. While living cells are fundamental to modern therapies, experimental workflows remain highly manual and disjointed. This fragmentation creates significant inefficiencies and slows the pace of scientific discovery and therapeutic innovation.
Critical research data is frequently scattered across spreadsheets, laboratory equipment, and disconnected software systems. This disorganization severely limits the ability of research teams to apply artificial intelligence tools effectively. Consequently, the processes for drug development and manufacturing are less efficient than they could be.
Introducing the Orbit Platform
The company's solution, named Orbit, is engineered to consolidate these fragmented workflows into a single, AI-native environment. This platform functions as a virtual control panel for the cell, connecting existing laboratory instruments and data sources. By centralizing information, Orbit provides a unified foundation for advanced biological analysis and experimentation.
Orbit incorporates virtual cell models and sophisticated AI research agents to help scientists better understand cellular behavior. These tools are designed to simulate biological responses and guide experimental decision-making with greater precision. The platform aims to help researchers identify patterns and assess outcomes more effectively than traditional methods allow.
Vision and Strategic Funding Allocation
Co-founder and CEO Alex Ward stated that the company was founded to overcome the difficulties researchers face in interpreting complex experiments. He emphasized that Orbit connects experimental data with AI models to make cell biology more understandable. The ultimate goal is to streamline the application of this knowledge to real-world therapeutic development.
The new funding will be strategically allocated to expand Tolemy Bio’s data generation, machine learning, and engineering capabilities. This investment will also fuel the continued enhancement of the Orbit platform. Furthermore, the capital will support early deployments with key customers and research partners in the industry.
The funding round saw participation from notable investors including Big Sur Ventures, JME Ventures, and Masia. While the company is headquartered in Cambridge, a significant portion of its operational activity will be based in Barcelona. This dual-location strategy allows the company to tap into distinct European talent pools for its expansion.
Tolemy Bio's long-term vision is to establish a virtual-cell platform that transforms biopharmaceutical research and development. By moving beyond traditional trial-and-error experimentation, the company aims to empower scientists with more precise, data-driven methods. This approach promises to accelerate the creation of next-generation therapies by providing unprecedented control over living cells.